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Background: Type 2 diabetes mellitus is frequently unrecognized until complications appear. Diabetic autonomic
neuropathy is one of the early complications of type 2 diabetes mellitus, resulting in autonomic nervous system
(ANS) dysfunction. The purpose of this study was to determine the validity of ANS function indicators to screen for
type 2 diabetes mellitus, as measured by the TM-Oxi and SudoPath system.
Methods: All enrolled participants completed a basic sociodemographic and medical history questionnaire
including current medications. Healthy controls (n = 25) underwent a 2-hour oral glucose tolerance test (OGTT) to
evaluate glucose, insulin, and insulin C-peptide. Patients with type 2 diabetes mellitus (n = 24) were assessed with
fasting plasma glucose (FPG) and glycosylated hemoglobin. The TM-Oxi and SudoPath system evaluation was
completed by all subjects. Data were analyzed using SPSS 22. Frequency and descriptive statistics were calculated
on all variables. The criterion for statistical significance was α = 0.05.
Results: The twenty-five healthy controls had a mean age of 37.0 years. The twenty-four type 2 diabetes mellitus
patients currently undergoing standard treatment had a mean age of 48.9 years. Based on the American Diabetes
Association guidelines, we detected pre-diabetes in 4 subjects and diabetes in 1 subject, while all other subjects had
normal FPG values. At 120 minutes, the correlations between the OGTT and cardiometabolic risk score (CMRS) were:
r = 0.56 (p = 0.004) for glucose and r = 0.53 (p = 0.006) for insulin. At 120 minutes, the correlations between the OGTT
and photoplethysmography index (PTGi) were: r = -0.56 (p = 0.003) for glucose and r = -0.41 (p = 0.04) for insulin.
The CMRS, PTGi, and plethysmography total power index (PTGVLFi) differed significantly between the diabetes
patients and healthy participants. The specificity and sensitivity for the CMRS, PTGi, and PTVLFi comparing the
diabetes patients with healthy controls were high.
Conclusion: The TM-Oxi and SudoPath system shows promise as a valid, convenient, and non-invasive screening
method for type 2 diabetes mellitus. The ANS function and CMR indicators measured by this system may be useful in
guiding diabetes and cardiovascular health screening, treatment, and monitoring.
Keywords: Type 2 diabetes mellitus, Diabetic autonomic neuropathy, Autonomic nervous system, Cardiometabolic risk,
Glycosylated hemoglobin, Oral glucose tolerance test* Correspondence: jelewis@miami.edu
1Department of Psychiatry & Behavioral Sciences, University of Miami Miller
School of Medicine, 1120 NW 14th Street, Suite #1474 (D28), Miami, FL
33136, USA
Full list of author information is available at the end of the article
© 2014 Lewis et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Figure 1 Photograph of the TM-Oxi and SudoPath system. This
machine is a software complex managing three FDA cleared
devices; a blood pressure device, an oximeter, and a galvanic skin
response device.
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The incidence of type 2 diabetes mellitus has increased
in recent decades to epidemic proportions. As of 2010,
25.8 million people in the U.S. were estimated to have
diabetes (90-95% of the cases were type 2 diabetes melli-
tus) [1], and according to the Centers for Disease Control
and Prevention, one in three children born in the year
2000 will eventually become diabetic [2,3]. Because the
complications of diabetes insidiously damage multiple
organ systems, type 2 diabetes mellitus has become a
major public health threat [4].
Early detection of diabetes is warranted for preventing
disease progression and its associated macrovascular
(coronary artery disease, peripheral arterial disease, and
stroke) and microvascular complications (diabetic nephrop-
athy, neuropathy, and retinopathy) [1,3,5]. One of the
poorly understood yet serious and most common compli-
cations of type 2 diabetes mellitus is diabetic autonomic
neuropathy (DAN) [6]. DAN can cause dysfunction of the
autonomic nervous system (ANS), which controls auto-
nomic body functions through the balanced opposition
of the parasympathetic (PNS) and sympathetic nervous
systems (SNS) [6]. Diabetes-associated metabolic distur-
bances (e.g., hyperglycemia) can lead to neuro-hormonal
growth deficiency in the ANS through deregulated cell
signaling pathways, direct neuronal damage, reduced neur-
onal blood flow, increased oxidative stress, and altered ni-
tric oxide (NO) homeostasis [7,8].
One of the clinical manifestations of DAN occurs in
the sudomotor system. The SNS controls sweat produc-
tion in the skin, but in patients with diabetes who also
have DAN, ANS dysfunction results in loss of sweating
and dry skin. Dry skin cracks, providing portals of entry
for microorganisms, which can lead to infectious ulcers,
gangrene, and amputation [8-10]. Other organ systems,
including the cardiovascular, gastrointestinal, genitouri-
nary, and ocular, are also susceptible to ANS dysfunction
in type 2 diabetes mellitus [8,11].
Cardiovascular autonomic neuropathy (CAN), a form
of DAN, is an early and frequent complication of type 2
diabetes mellitus that may occur within one year of diag-
nosis in up to 20% of patients with diabetes [8,12,13].
CAN is a consequence of damage to autonomic nerve
fibers that innervate the heart and cardiac blood vessels,
resulting in abnormalities in heart rate (i.e., reduced heart
rate variability) and vascular dynamics (i.e., abnormal
blood flow, volume, and pressure) [8,14]. Both DAN and
CAN develop silently and slowly over years and represent
early complication of type 2 diabetes mellitus.
Autonomic function tests can detect ANS dysfunction
at an early stage in asymptomatic type 2 diabetes mellitus
patients [8,14]. In the early 1970s, several noninvasive
cardiovascular reflex tests were proposed to assess cardio-
vascular autonomic function in order to diagnose CAN[8,15]. Those tests included the Valsalva maneuver, deep
breathing, and heart rate and blood pressure response to
standing up. Furthermore, ANS function in the sudomo-
tor system can be assessed by measuring the sympathetic
skin response generated on the sweat glands and the
overlying epidermis [8]. Thus, the TM-Oxi and SudoPath
system was designed to evaluate ANS function by measur-
ing changes in heart rate, vascular dynamics, and skin
response during the performance of those autonomic
function tests. The measurements are integrated with
anthropometric, physical activity, and endothelial func-
tion data in software to calculate various cardiovascular
ANS function indicators, such as a photoplethysmographic
(PTG) very low frequency index (PTGVLFi), a PTG index
(PTGi), and a cardiometabolic risk score (CMRS).
ANS dysfunction and CMR indicators calculated by
the TM-Oxi and SudoPath system may be effective in
detecting pre-clinical disease and improving the manage-
ment of type 2 diabetes mellitus [5,8]. Existing screening,
diagnostic, and monitoring methods for type 2 diabetes
mellitus are all invasive, time consuming, and involve
some level of discomfort to the participant. Furthermore,
approximately one-third of the individuals with type 2
diabetes mellitus are undiagnosed [3]. Therefore, a rapid,
non-invasive, and inexpensive screening device such as
the TM-Oxi and SudoPath system may facilitate early
detection and improve management of the disease. The
purpose of this study was to determine the validity of
ANS function and CMR indicators, calculated by the
TM-Oxi and SudoPath system, in screening for type 2
diabetes mellitus.
Methods
The TM-Oxi and SudoPath system
The TM-Oxi assesses cardiac sympathetic and parasym-
pathetic ANS function using an automatic oscillometric
blood pressure device and a pulse oximeter (Figure 1).
The pulse oximeter device uses an optical technique to
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Briefly, light of a suitable wavelength that is directed into
the nail bed area of the right index finger is absorbed,
reflected, and scattered by blood hemoglobin. During
systole, the arterial diameter increases as blood fills the
fingertip capillary beds, and the presence of more
hemoglobin in the vessels alters the absorption, reflec-
tion, and scattering of the light, measured by a photosen-
sor. This creates a pulsatile signal or waveform illustrated
as a PTG that varies in time with each heartbeat. The
PTG is used to analyze heart rate variability (HRV), de-
fined as the variation in time intervals between each heart
beat (i.e., R-R interval) that results from PNS and SNS
activity on the heart’s sinus node [16,17].
The TM-Oxi software uses the PTG to analyze spontan-
eous HRV and of experimentally induced fluctuations of
the R-R intervals during cardiovascular autonomic reflex
tests (i.e., Valsalva maneuver, deep breathing, and change in
posture) [18], as discussed at the manufacturer’s website
(http://www.ldteck.com/endothelial-dysfunction.html). The
patented signal processing and analysis of the TM-Oxi
(Patent PCT/IB2013/002595) applies a mathematical algo-
rithm, the fast Fourier transform (FFT), to the PTG
recording (FFTPTG) to analyze the three frequency
components of HRV (Figure 2): (a) a very low frequency
(PTGVLF) component associated with thermoregulation
and sweating due to oscillations in vasomotor tone (sym-
pathetic control); (b) a low frequency (PTGLF) compo-
nent related to the baroreflex, which is under sympathetic
control with parasympathetic modulation; and (c) a highFigure 2 Current peaks during electrical stimulation of the skin.
The blue current peak corresponds to hyperemia, and the white
current peak corresponds to chloride release via the sweat glands. In
the ordinate, current peaks in conductance are expressed in
micro-siemens, and the abscissa is expressed in time in seconds.frequency (PTGHF) component associated with R-R
changes during the phases of breathing that is under
parasympathetic control. Parameters calculated from
these components include: (a) PTG total power (PTGTP),
which is the sum of the areas under the curve covered by
the 3 frequency components; (b) PTGi, which is the sum
of the amplitudes of the 3 frequency components; and (c)
PTGVLFi, which is the ratio between PTGVLF and the
electric skin response to nitric oxide (ESRNO), a marker
related to skin blood flow, derived from the SudoPath (de-
scribed below), as detailed at the manufacturer’s website
(http://www.ldteck.com/endothelial-dysfunction.html).
Besides assessing autonomic function, PTG also pro-
vides information about endothelial function and arterial
stiffness. The PTG signal is also quantized into a digital
volume pulse (DVP) waveform that represents the pres-
sure wave that propagates from the heart to the periphery
(i.e., systolic peak) and reflection back to the heart (i.e.,
diastolic peak) during the cardiac cycle [19-21]. Arterial
stiffness, partially as a result of endothelial dysfunction, is
defined as the arterial opposition to the pressure wave,
resulting in abnormal systolic and diastolic peaks. Thus,
the DVP contour, although affected by body temperature
and perfusion, is mainly determined by myocardial and
arterial characteristics, and it is used by the TM-Oxi to
calculate variables (i.e., systolic/diastolic peaks, reflection
index, and stiffness index) that are indicators of vascular
health and arterial status. Finally, PTG is used by the
TM-Oxi to calculate the CMRS. The CMRS is calcu-
lated using the following variables from the TM-Oxi:
systolic and diastolic blood pressure, body mass index
(BMI), physical activity level, endothelial function, and
ANS function indicators. Each variable is scored as 0 =
normal, 1 = borderline, or 2 = abnormal to calculate the
CMRS.
The SudoPath uses two stainless steel electrodes
placed under the soles of the feet, where sweat gland
density is very high. It assesses galvanic skin response by
measuring the electrical conductance of the skin, which
is dependent on the amount of sweat-induced moisture,
and hence, is indicative of SNS function. The patented
device (US patent number 61835064) generates a low
voltage signal with weak DC current that is fed to the
active electrode, passing through the interstitial fluid
and reaching the skin in contact with the passive elec-
trode. The current provokes an electrical stimulation
of the post-sympathetic cholinergic fiber, which re-
leases acetylcholine, stimulating nicotinic muscarinic
receptors (M-receptors) in the skin and sweat glands
[22]. In endothelial cells, M-activation results in increased
NO that causes relaxation and vasodilation in adjacent
vascular smooth muscle, thus increasing blood flow. In
the sweat gland, activation of M-receptors promotes
chloride movement across the apical membrane of the
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tential that drives sodium and water into the lumen for
sweat production [23]. The change in sweat production
and blood flow affects the electrical conductance of the
skin, which is measured by the device. Figure 3 represents
the measured conductance provoked by the electrochem-
ical reaction of water and chloride ions on the bulk of the
electrodes, which is measured as ESRNO. This method is
fully described at the manufacturer’s website (http://www.
ldteck.com/galvanic-skin-response.html).
Study participants
The study was conducted with the approval of the Uni-
versity of Miami Institutional Review Board for human
subjects research. Each participant signed informed con-
sent and HIPAA forms prior to study entry. Potential
participants (n = 80) were identified through referrals at
the University of Miami Miller School of Medicine from
April 2013 to February 2014. Of 55 eligible participants,
50 were enrolled in the study, and the other 5 decided
not to participate. One type 2 diabetes mellitus patient
was eliminated from the subsequent data analysis be-
cause of a poor quality signal from the TM-Oxi.
Inclusion and exclusion criteria
Inclusion criteria were: (a) 18+ years of age; (b) English
or Spanish speaking; (c) ability to provide written in-
formed consent; and (d) diagnosed with type 2 diabetes
mellitus or healthy with no known chronic diseases or
disorders. Exclusion criteria were: (a) diagnosis of type 1
diabetes, HIV/AIDS, active cancer and/or current chemo-
therapy or radiation treatment, hypothyroidism, atrioven-
tricular block, Raynaud’s disease, Alzheimer’s disease,
or Parkinson’s disease; (b) current use of alpha or betaFigure 3 Fast Fourier transform (FFT) of a photoplethysmograph
waveform. The waveform in the frequency domain is separated into
three frequency bands: the ‘very low frequency or PTGVLF’ (in green),
the ‘low frequency or PTGLF’ (in yellow), and the ‘high frequency or
PTGHF’ (in blue). All area measurements are expressed in millisecond
square (ms2). In the ordinate, the FFT amplitude is in millivolts (mV),
and in the abscissa the band of frequency is in Hertz (Hz).blockers or corticosteroids; (c) contraindications to the
use of the TM-Oxi and SudoPath system, including
presence of an automatic implantable defibrillator,
erratic, accelerated, or mechanically-controlled irregular
heart rhythms, arterial fibrillation/flutter, or any implanted
electronic device; or (d) an acrylic nail or nail polish on
the right index finger.
Outcomes and assessments
All enrolled participants completed a basic sociodemo-
graphic and medical history questionnaire including
current medications. All participants were instructed to
fast for a minimum of 8 hours prior to blood sampling.
Healthy subjects underwent a two-hour OGTT to evalu-
ate glucose, insulin, and insulin C-peptide. Type 2 diabetes
mellitus patients were assessed with venous fasting plasma
glucose (FPG) and glycosylated hemoglobin (GHb). The
TM-Oxi and SudoPath system evaluation was completed
by all subjects.
Statistical analysis
Data were analyzed using SPSS 22 (IBM Inc., Chicago, IL)
for Windows. Frequency and descriptive statistics were
calculated on all variables. Independent-sample t-test and
chi square were utilized to determine the presence of
differences in background contextual variables by group
assignment. For healthy subjects, we evaluated the OGTT
results at 120 minutes for the detection of pre-diabetes
and diabetes according to standard criteria. We used
Pearson product-moment correlations between the
CMRS and PTGi and OGTT values. Healthy subjects
and type 2 diabetes mellitus patients were compared
with t-tests and receiver operating characteristic (ROC)
curves to determine the specificity and sensitivity of the
CMRS and PTGVLFi and PTGi as potential screening
markers of diabetes. The criterion for statistical signifi-
cance was α = 0.05.
Results
Safety and tolerability
No adverse events were reported with the use of the
TM-Oxi and SudoPath system during the study.
Sociodemographics and health variables
Table 1 displays the characteristics for each study group.
Forty-nine subjects (n = 25 healthy controls and n = 24
patients with type 2 diabetes mellitus) were included in
the study. The twenty-five healthy controls (12 males
and 13 females) had a mean age of 37.0 years (SD = 17.5;
R = 18, 78) and a mean BMI = 26.1 (SD = 5.6; R = 17.2,
43.6). The twenty-four type 2 diabetes mellitus patients
currently undergoing standard treatment (12 males and 12
females) had a mean age of 48.9 years (SD = 11.0; R = 30,
72) and a mean BMI = 34.6 (SD = 8.3; R = 23.3, 56.1). The
Table 1 Sociodemographic characteristics of the sample
Variable Category Diabetes patients (n = 24) Healthy controls (n = 25) Statistic, p value
Age - 48.9 ± 11.0 (30, 72) 37.0 ± 17.5 (18, 78) t(47) = 2.8, p = 0.01
Gender Male 12 (50%) 12 (48%) Χ2(1) = 0.02, p = 0.89
Female 12 (50%) 13 (52%)
Race/Ethnicity White, non-Hispanic 1 (4%) 11 (44%) Χ2(4) = 19.3, p = 0.001
Black, non-Hispanic 9 (38%) 0
Hispanic 13 (54%) 13 (52%)
Asian 1 (4%) 0
Middle Eastern 0 1 (4%)
BMI (kg/m2) - 34.6 ± 8.3 (23.3, 56.1) 26.1 ± 5.6; (17.2, 43.6) t(47) = 4.2, p < 0.001
SBP (mm Hg) - 138.1 ± 18.6 (102, 194) 120.4 ± 14.2 (4, 165) t(47) = 3.8, p < 0.001
DBP (mm Hg) - 79.6 ± 8.9 (63, 96) 75.1 ± 12.5 (52, 104) t(47) = 1.5, p = 0.15
FPG (mg/dL) - 131.7 ± 50.1 (79, 243) 85.2 ± 6.9 (72, 105) t(47) = 4.6, p < 0.001
Note: Continuous data are represented by M ± SD (R); SBP = Systolic blood pressure SBP = Systolic blood pressure; DBP = Diastolic blood pressure; FPG = Fasting
plasma glucose.
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more likely to be black, and had a higher BMI, systolic
blood pressure, and FPG (see Table 1). The duration of
diagnosis of diabetes for the patients was: 10 or more years
(40%; n = 10), 5 to 9 years (45%; n = 11), and less than
5 years (15%; n = 3). The type 2 diabetes mellitus patients
had a mean GHb of 7.0% (53 mmol/mol) (SD = 1.3%
(14.2 mmol/mol); R = 5.4%, 10.4% (36, 90 mmol/mol)). The
primary treatments for the type 2 diabetes mellitus patients
were: metformin (68%; n = 16), a secretagogue (28%; n = 7),
insulin (5%; n = 1), and an antihypertensive (36%; n = 9).
Evaluation of diabetes risk among healthy subjects
Based on the American Diabetes Association guidelines,
we detected pre-diabetes in 4 subjects (16%; values = 140,
143, 147, and 153 mg/dL) and diabetes in 1 subject (4%;
value = 254 mg/dL), while all other subjects had normal
glucose values (i.e., 139 mg/dL or less).
Correlations between glucose, insulin, and insulin C-peptide
from OGTT at 120 minutes with CMRS and PTGi
At 120 minutes, the correlations between the OGTT
and CMRS were: r = 0.56 (p = 0.004) for glucose, r = 0.53
(p = 0.006) for insulin, and r = 0.58 (p = 0.002) for insulin
C-peptide. At 120 minutes, the correlations between the
OGTT and PTGi were: r = -0.56 (p = 0.003) for glucose,
r = -0.41 (p = 0.04) for insulin, and r = -0.50 (p = 0.01)
for insulin C-peptide.
Comparisons between the healthy subjects and type 2
diabetes mellitus patients
The mean CMRS of the healthy subjects was 2.2 (SD = 2.9;
R = 0, 9) and of the type 2 diabetes mellitus patients was 9.4
(SD = 3.7; R = 1, 14), and that difference was statistically
significant (t = 7.6 (47), p < 0.001). The mean PTGi of thehealthy subjects was 67.0 (SD = 25.0; R = 18.4, 123.3)
and of the type 2 diabetes mellitus patients was 31.3
(SD = 11.5; R = 12.3, 68.5), and that difference was sta-
tistically significant (t = 6.4 (47), p < 0.001). The mean
PTGVLFi of the healthy subjects was 27.7 (SD = 52.6;
R = 3, 242) and of the type 2 diabetes mellitus patients
was 61.8 (SD = 40.7; R = 12, 190), and that difference
was statistically significant (t = 2.5 (47), p = 0.02).
Receiver operating characteristic curves
The CMRS had a sensitivity of 92% and specificity of 83%
(cut-off score > 4) with an area under the curve = 0.94
(SE = 0.04; 95% CI = 0.87, 1.0) and an asymptotic signifi-
cance < 0.001 (Figure 4). The PTGi had a sensitivity of
92% and specificity of 80% (cut-off score > 35.5) with the
area under the curve = 0.92 (SE = 0.04; 95% CI = 0.84, 1.0)
and an asymptotic significance < 0.001 (Figure 5). The
PTGVLFi had a sensitivity of 92% and specificity of
87% (cut-off score > 25.5) with the area under the
curve = 0.91 (SE = 0.05; 95% CI = 0.81, 1.0) and an
asymptotic significance < 0.001 (Figure 6).
Discussion
In our study, the TM-Oxi and SudoPath system was useful
for detecting the presence of type 2 diabetes mellitus
through its ability to assess ANS function. Currently used
screening tests for type 2 diabetes mellitus are invasive,
time-consuming, and have other disadvantages [24]. Al-
though the 2-hour OGTT is the gold standard for diabetes
testing [5], it is time consuming, not easily reproducible,
affected by short-term lifestyle changes, and expensive
[25]. For those reasons, the American Diabetes Associ-
ation recommends screening for type 2 diabetes mellitus
with FPG or GHb (FPG ≥ 126 mg/dl or GHb ≥ 6.5% or
48 mmol/mol) [3,26].
Figure 6 Receiver operating characteristic curve for the
photoplethysmographic very low frequency. The curve
represents the sensitivity and specificity for the
Photoplethysmographic Very Low Frequency.
Figure 4 Receiver operating characteristic curve for the
cardiometabolic risk score. The curve represents the sensitivity
and specificity for the Cardiometabolic Risk Score.
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including moderate sensitivity when compared to OGTT
[24,27-29]. One population-based study of 2,753 partici-
pants showed that the correlations of FPG and GHb
with OGTT were moderate at best (r = 0.46 and r = 0.33,
respectively) [24]. When used as a sole screening test for
type 2 diabetes mellitus, the sensitivity of FPG can be asFigure 5 Receiver operating characteristic curve for the
photoplethysmographic index. The curve represents the sensitivity
and specificity for the Photoplethysmographic Index.low as 40%, whereas the specificity is about 84% [27].
Additionally, a multitude of reports have indicated that
up to 50% of patients with diabetes who were diagnosed
by OGTT criteria would have been missed by FPG cri-
teria [30]. Measurement of GHb with a cut-point ≥ 6.5%
or 48 mmol/mol is reasonably specific (> 88%), however
the sensitivity ranges from 17% to 72.8% [28,29]. In our
study, CMRS and PTGi variables demonstrated signifi-
cant correlations with the 2-hour OGTT glucose. This is
an improvement compared to the results of GHb and
FPG in other research [24]. Furthermore, the CMRS,
PTGi, and PTGVLFi were significantly different between
type 2 diabetes mellitus and healthy participants. The
specificity and sensitivity in differentiating patients with
diabetes and healthy controls were high for each indica-
tor. Thus, our results indicate the TM-Oxi and SudoPath
system may prove useful as a screening tool for type 2
diabetes mellitus.
Another potential benefit of this system is to detect
cardiovascular complications in the same patient popula-
tion. The link between type 2 diabetes mellitus and CVD
has been demonstrated in numerous studies [31]. CVD
is listed as the cause of death in approximately 65% of
individuals with type 2 diabetes mellitus. Individuals
with diabetes not only face a higher mortality rate from
CVD, but also a worse prognosis for survival than do
CVD patients without diabetes. Detecting both the
presence of diabetes and CVD development with the TM-
Oxi and SudoPath system becomes relevant in reducing
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linked diseases. More importantly, the Subcommittee of
the Toronto Consensus Panel on Diabetic Neuropathy
recommends early screening of CAN for all patients with
diabetes because it is often asymptomatic [18] and may
have detrimental clinical consequences (e.g., silent myo-
cardial infarction, ischemia, cardiorespiratory arrest, ven-
tricular arrhythmia, left ventricular dysfunction, resting
tachycardia, postural hypotension, and diabetic nephropa-
thy, among others) [32,33].
Furthermore, endothelial dysfunction and arterial stiff-
ness are associated with insulin resistance in type 2
diabetes mellitus [34,35]. The confluence of diabetes
associated metabolic disturbances (i.e., hyperglycemia
and dyslipidemia) with inflammatory mediators, platelets,
and the vascular wall results in accelerated atherogenesis
via endothelial dysfunction and arterial stiffening, leading
to increased cardiovascular risk [20]. In our study, the
measured indicators of endothelial dysfunction and arter-
ial stiffness were used to calculate CMRS. These indicators
along with CMRS could be used to assess the overall
cardiovascular risk, in addition to those related to CAN,
in type 2 diabetes mellitus patients.
Conclusion
In sum, we have demonstrated that the TM-Oxi and
SudoPath system may be useful in diabetes screening and
treatment monitoring. Current standard testing, when ap-
plied to screening large populations of asymptomatic indi-
viduals, and monitoring those who have been positively
identified as having type 2 diabetes mellitus can be costly
[27]. Furthermore, the demand is increasing for the de-
velopment of low-cost, simple, and portable technolo-
gies to be used in the community and clinical setting.
The TM-Oxi and SudoPath assessment is also non-
invasive, which is relevant to approximately 10% of indi-
viduals in medical settings who have an excessive fear of
needles that can result in avoidance and distress. Finally,
the assessment is quick to perform, since it only takes
approximately 10 minutes to complete, and the results
are available immediately.
Limitation of study
Limitations of our study include a relatively small sample
size, a disproportionately greater number of Caucasians in
the healthy control group, and a significant difference in
average age between groups. Additionally, the OGTT
was not administered on type 2 diabetes mellitus
patients, and GHb was not measured in the healthy
subjects. Nonetheless, our study demonstrated that the
TM-Oxi and SudoPath system shows promise as a
screening tool for type 2 diabetes mellitus. The ANS
function and indicators measured by this system may
be useful in guiding diabetes and cardiovascular healthscreening, treatment, and monitoring. Larger scale studies
are warranted to substantiate these results and explore the
clinical and prognostic significance of the scoring system
and various indicators.
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